| Period | Period Low | Period High | Performance | |
|---|---|---|---|---|
| 1-Month | 60.000 +6.67% on 03/04/26 | | 75.000 -14.67% on 03/16/26 | -3.429 (-5.09%) since 02/27/26 |
| 3-Month | 48.000 +33.33% on 02/02/26 | | 75.000 -14.67% on 03/16/26 | +6.000 (+10.34%) since 12/31/25 |
| 52-Week | 26.000 +146.15% on 05/27/25 | | 84.000 -23.81% on 12/17/25 | +30.500 (+91.04%) since 04/01/25 |
Avacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted oncology drugs and powerful diagnostics, announces that the first patient has been dosed in the US under its Investigational...
Avacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted oncology drugs and powerful diagnostics, announces that the first patient has been dosed in the fifth cohort of the...
Avacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted oncology drugs and powerful diagnostics, today announced the appointment of Karen Harrison as Chief Operating Officer...
Avacta Group plc (AIM: AVCT), a clinical stage oncology drug company and developer of powerful diagnostics based on its innovative Affimer ® and pre|CISION™ platforms, announces that the US Food and...
Avacta Group plc (AIM: AVCT), a clinical stage biopharmaceutical company developing innovative cancer therapies and powerful diagnostics based on its proprietary Affimer ® and pre|CISION™ platforms,...
Avacta Group plc (AIM: AVCT), a clinical stage oncology drug company and developer of powerful diagnostics based on its innovative Affimer® and pre|CISION™ platforms, is pleased to announce that a milestone...
| 3rd Resistance Point | 68.667 |
| 2nd Resistance Point | 67.333 |
| 1st Resistance Point | 65.667 |
| Last Price | 64.000 |
| 1st Support Level | 62.667 |
| 2nd Support Level | 61.333 |
| 3rd Support Level | 59.667 |
| 52-Week High | 84.000 |
| Last Price | 64.000 |
| Fibonacci 61.8% | 61.844 |
| Fibonacci 50% | 55.000 |
| Fibonacci 38.2% | 48.156 |
| 52-Week Low | 26.000 |